Vijesh A.M.,SeQuent Scientific |
Vijesh A.M.,National Institute of Technology Karnataka |
Isloor A.M.,National Institute of Technology Karnataka |
Prabhu V.,Veterinary College |
And 2 more authors.
European Journal of Medicinal Chemistry | Year: 2010
In the present study a series of novel 2,4-disubstituted thiazole derivatives containing substituted pyrazole moiety was synthesized by the reaction of 3-Aryl-1H-pyrazole-4-carbaldehyde thiosemicarbazone with 6-Bromo/H-3-(bromoacetyl)-2H-chromen-2-one/phenacyl chloride. Structures of newly synthesized compounds were characterized by spectral studies. New compounds were screened for their antibacterial studies against Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa. The results revealed that compounds 7c, 8e, and 8f having 2,5-dichlorothiophene substituent and 8c, 8d having 2,4-dichlorophenyl substituent showed significant antibacterial activity against all tested microorganisms. © 2010 Elsevier Masson SAS. All rights reserved.
SeQuent Scientific | Date: 2011-11-23
The present invention discloses a novel, cost-effective process for preparation of a benzimidazole carbamates compound. Specifically, it relates to the process for the preparation of anti-parasite bulk drug albendazole. The process comprises a) thiocyanating 2-nitroaniline of formula VI with ammonium thiocyanated in presence of a halogen to obtain 2-nitro-4-thiocyanoaniline of formula V; b)propylating 2-nitro-4-thiocyanoaniline of formula V with propylbromide in presence of n-propanol and a base in absence of a phase transfer catalyst to obtain 4-propylthio-2-nitroaniline of formula III; C) reducing the nitro group of 4-propylthio-2-nitroaniline prepared in step b) by reacting an aqueous alkali metal sulphide or an alkaline metal sulphide to obtain 4-propylthio-o-phenylenediamine of formula II; and d)condensing 4-propylthio-o-phenylenediamine of formula II with alkali or alkaline earth metal salt of methylcyano carbamate in presence of an acid to form Albendazole of formula I.
SeQuent Scientific | Date: 2010-06-08
SeQuent Scientific | Date: 2013-02-20
The present invention relates to a process for the preparation of succinylcholine chloride, a pharmaceutically active compound used as skeletal muscle relaxant which comprises condensing succinic anhydride with N,N-diemthylaminoethanol using a catalyst in presence of a solvent to form bis[2-(dimethylamino)ethyl]succinate; in situ purifying the bis[2-(dimethylamino)ethyl]succinate using a base; reacting pure bis[2-(dimethylamino)ethyl]succinate with methyl chloride gas using an alcohol; and purifying the obtained crude succinylcholine chloride using water and alcohol.
News Article | June 3, 2014
Bangalore-based SeQuent Scientific Ltd, which recently strategised to focus on its veterinary active pharmaceutical ingredients (APIs) and formulations apart from niche human API business, is scouting for potential acquisition targets in India and overseas, a top executive of the company told VCCircle. “We are looking at strengthening our global operations through strategic acquisitions. The rationale behind overseas acquisitions would be to increase access to markets and for domestic targets it would be to increase scale of operations in India,” said Manish Gupta, CEO of SeQuent. While the company would look at these acquisitions in both core areas – veterinary (API and formulation) and human API – it would have a bias for the former which will form a larger part of the overall business, Gupta added. This is part of the expansion strategy of the company where it is targeting its veterinary business to grow to a size of Rs 1,000 crore in three to four years. “We are looking at growth of around four times for our veterinary business which at present is around Rs 250-300 crore,” Gupta said. Further, while veterinary API business is around 75 per cent and formulations around 25 per cent, the latter could see a stronger rate of growth. SeQuent in the last one year has decided to focus on its veterinary and human API business and divest other assets. While the veterinary business stands at 60 per cent of the overall revenue, it is likely to claim a larger share in the next few years. “From 2013, we embarked on a very clear strategy to focus on our veterinary business and human API business. The other businesses have been divested or we have exited through closure of whatever other related activities we had,” said Gupta, who joined the company six months ago. As part of this restructuring, earlier this year, the company sold its specialty chemical business to South Korea-based Songwon Industrial Group for an undisclosed amount. It also formed a joint venture with Shasun Pharmaceuticals Ltd to launch its veterinary business under Alivira Animal Health Ltd where SeQuent holds around 73 per cent and the rest is owned by Shasun. Later Ascent Capital picked minority stake in the company for Rs 120 crore. Further, promoters of SeQuent have also been investing in the company. “As part of implementing the new strategy, cleaning up past balance sheet issues and requirement of growth capital, the promoters of the group have been investing in the company through several rounds. Between that and growth capital from Ascent Capital, we have enough to fund our acquisitions,” he added. The promoters held around 65.35 per cent stake in the company as of March 31, 2014 with warrants which would push up their holding to around 69 per cent. Earlier this week, Agnus Capital and Chayadeep Ventures – investment vehicles of promoters of SeQuent – infused Rs 44.4 crore to pick up fresh warrants which would push up the promoter holding to around 71 per cent. The company’s board has also approved issue of more equity convertible warrants. In FY14, revenue of the company climbed 40 per cent to Rs 455 crore but losses mounted to Rs 110 crore due to one-time expense related to its decision to exit Penems project and a few overseas units.